new_0222_0360|TARS|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0360|TARS|1|Tarsus Pharmaceuticals Inc Total Current Assets (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Cash and Short Term Investments (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Inventories (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Net PP&E (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Goodwill and Intangibles (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Total Liabilities (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Total Current Liabilities (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Total Long Term Liabilities (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Total Deposits (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Book Value (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Retained Earnings (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Treasury Stock (Quarterly) (USD)|Tarsus Pharmaceuticals Inc EV to Revenues|Tarsus Pharmaceuticals Inc EV to Earnings|Tarsus Pharmaceuticals Inc EV to Free Cash Flow|Tarsus Pharmaceuticals Inc EV to Assets (Quarterly)|Tarsus Pharmaceuticals Inc PS Ratio|Tarsus Pharmaceuticals Inc PE Ratio|Tarsus Pharmaceuticals Inc Price to Book Value|Tarsus Pharmaceuticals Inc PEG Ratio|Tarsus Pharmaceuticals Inc Debt to Equity Ratio|Tarsus Pharmaceuticals Inc Dividend Yield|Tarsus Pharmaceuticals Inc Shareholder Yield (TTM)|Tarsus Pharmaceuticals Inc Percent of Shares Outstanding Short|Tarsus Pharmaceuticals Inc Total Receivables (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Total Payables (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Total Capital Stock (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Return on Invested Capital|Tarsus Pharmaceuticals Inc Quality Ratio Score|Tarsus Pharmaceuticals Inc Momentum Score|Tarsus Pharmaceuticals Inc Beta (1Y)|Tarsus Pharmaceuticals Inc Sustainable Growth Rate (TTM)|Tarsus Pharmaceuticals Inc Institutional Investor Ownership Percentage|Tarsus Pharmaceuticals Inc Average Diluted Shares Outstanding (Quarterly)|Tarsus Pharmaceuticals Inc Total Employees (Annual)|Tarsus Pharmaceuticals Inc EPS Diluted (Quarterly) (USD)|Tarsus Pharmaceuticals Inc SG&A Expense (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Shares Outstanding|Tarsus Pharmaceuticals Inc Repurchase of Capital Stock (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Ordinary Shares Number (Quarterly)|Tarsus Pharmaceuticals Inc Payout Ratio|Tarsus Pharmaceuticals Inc Quick Ratio (Quarterly)|Tarsus Pharmaceuticals Inc Normalized Diluted EPS (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Stock Buybacks (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Effective Tax Rate (TTM)|Tarsus Pharmaceuticals Inc Return on Equity|Tarsus Pharmaceuticals Inc Net Income (TTM) (USD)|Tarsus Pharmaceuticals Inc Revenue (TTM) (USD)|Tarsus Pharmaceuticals Inc Dividend Per Share (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Revenue (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Gross Profit (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Pre-Tax Income (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Net Income (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Net Interest Income (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Price (USD)|Tarsus Pharmaceuticals Inc Total Return Price (USD)|Tarsus Pharmaceuticals Inc Enterprise Value (USD)|Tarsus Pharmaceuticals Inc 30-Day Average Daily Volume|Tarsus Pharmaceuticals Inc 1 Year Price Returns (Daily)|Tarsus Pharmaceuticals Inc Short Interest|Tarsus Pharmaceuticals Inc PE Ratio (Forward)|Tarsus Pharmaceuticals Inc PE Ratio (Forward 1y)|Tarsus Pharmaceuticals Inc PS Ratio (Forward)|Tarsus Pharmaceuticals Inc PS Ratio (Forward 1y)|Tarsus Pharmaceuticals Inc Quarterly EPS Estimates (USD)|Tarsus Pharmaceuticals Inc Quarterly Revenue Estimates (USD)|Tarsus Pharmaceuticals Inc Quarterly EPS Surprise|Tarsus Pharmaceuticals Inc Quarterly Revenue Surprise|Tarsus Pharmaceuticals Inc Quarterly Actual EPS (USD)|Tarsus Pharmaceuticals Inc Quarterly Actual Revenue (USD)|Tarsus Pharmaceuticals Inc Revenue Estimates for Current Fiscal Year (USD)|Tarsus Pharmaceuticals Inc Revenue Estimates for Next Fiscal Year (USD)|Tarsus Pharmaceuticals Inc Price Target (USD)|Tarsus Pharmaceuticals Inc Consensus Recommendation|Tarsus Pharmaceuticals Inc Price Target Num Estimates|Tarsus Pharmaceuticals Inc EPS Estimates for Current Fiscal Year (USD)|Tarsus Pharmaceuticals Inc EPS Estimates for Next Fiscal Year (USD)|Tarsus Pharmaceuticals Inc Research and Development Expense (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Reconciled Depreciation (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Non-Operating Interest Expense (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Land and Improvements (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Buildings and Improvements (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Other Properties (Quarterly) (USD)|Tarsus Pharmaceuticals Inc Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0360|TARS|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0360|TARS|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|monthly|quarterly|quarterly|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0360|TARS|5|106.5|106.5||106.5||106.5|106.5|106.5||106.5|106.5||||1.44755244755|91.5|||1.44755244755||91.5|1.44970414201||15.2666666667|106.5|106.5|106.5|||31|30.6666666667||30.5|91.375|92|91.375|91.375|35.5454545455|91.2|106.5||91.5|91.375||91.4||91.4|||91.5|91.3333333333|91.375|91.375|91.375|1.44970414201|1.44970414201|1.44970414201|1.4498381877|1.43023255814|15.2666666667|||1.44755244755|1.44755244755|91.3333333333|91.3333333333|91.25|91.5|91.25|91.25|20.7272727273|35|27.1176470588|13.9696969697|27.1176470588|22.8|28.4375|91.375|91.375||||106.5|106.5||
new_0222_0360|TARS|6|6|6||6||6|6|6||6|6||||286|2|||286||2|338||30|6|6|6|||2|3||14|8|1|8|8|11|5|6||2|8||5||5|||2|6|8|8|8|338|338|338|309|86|30|||286|286|9|9|4|2|4|4|22|13|17|33|17|20|16|8|8||||6|6||
new_0222_0360|TARS|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0360|TARS|201909||||||||||||||||||||||||||||||||||10.9008||-0.0625|0.234||||||-0.06|||||||||-0.681|-0.681|-0.021||||||||||||||||||||||||0.399|0.009|||||||
new_0222_0360|TARS|201912|58.03|57.952||0.28||64.321|0.819|63.502||-6.005|-6.034||||||||||||||0.036|0.456|0.002|||||||10.9008||-0.1295|0.387|||18.759|||-0.1016|||||||||-1.412|-1.412|-0.024||||||||||||||||||||||||0.697|0.019||||0.218|0.031||
new_0222_0360|TARS|202003||||||||||||||||||||||||||||||||||10.9008||-0.1795|0.606||-0.027||||-0.1795|||||||||-1.957|-1.957|0.161||||||||||||||||||||||||1.512|0.015|||||||
new_0222_0360|TARS|202006|54.706|53.135||1.395||3.872|3.075|0.797||52.367|-11.241||||||||||||||0.002|1.42|0.001|||||||10.9008||-0.2981|1.526||-0.001|18.759|||-0.2981||||-7.3|||||-3.25|-3.25|0.013||||||||||||||||||||||||1.737|0.017||||1.026|0.35||
new_0222_0360|TARS|202009|89.072|86.329||1.363||110.014|6.144|103.87||-17.829|-21.379|||||||||||||0.6997|0.001|4.706|0.002||||||57.7574|18.759|18|-0.5404|2.15|19.259|0.028|18.759|||-0.5404||-0.006||-16.757|||||-10.137|-10.138|0.004|20.44|20.44|307.325|73021.5667||134748|||||-0.5367||7.0378||-0.4989||||39.8|1|5|-1.9575|-2.5725|7.991|0.024||||0.977|0.369|24.17|
new_0222_0360|TARS|202012|170.655|168.129||1.236||5.992|5.387|0.605||165.98|-32.845||||-31.1118||||5.0606|||||1.9612|0.02|2.237|0.004|||||||20.3232|20|-0.5642|3.89|20.3232|-0.028|20.3232|||-0.5642||-0.0037||-26.812|||||-11.467|-11.467|0.01|41.33|41.33|671.8289|145568.4||398570|||13.4683|128.2378|-0.68||17.025||-0.5642|||||1||-2.6067||7.587|0.04||||0.861|0.368|37.7|36.25
new_0222_0360|TARS|202103|191.451|156.179||1.173||10.722|10.118|0.604||183.232|-22.469||||-16.0263|2.6054|||3.6102|||||1.9795|32.446|5.31|0.004|||||||21.8246||0.47|5.16|20.5245||20.5245||18.6425|0.47||-2.2167||-14.479|||33.432|32.135|10.689|10.376|0.009|32.23|32.23|505.3256|36852.9||406287|||10.6069|100.9931|-0.135|5|448.1481|568.64|0.47|33.432|16.6667|5|40.4|1|5|-3.06|-5.87|16.261|0.064||||0.751|0.401|30.72|33.32
new_0222_0360|TARS|202106|200.904|176.735||1.021||10.979|10.455|0.524||192.471|-16.124||||-51.7645|2.0619|||3.0978|||||1.5433|20.157|3.645|0.004|||||||21.9666||0.29|6.794|20.574||20.574||18.8323|0.3297||-7.5534||-4.884|||22.017|21.28|6.374|6.345|0.007|28.98|28.98|419.4995|94439.7333||317509|||9.5603|91.0282|-0.33|4.5333|199.5455|385.6695|0.3285|22.017|44.3235|5|51.2|1|5|-1.08|-5.92|7.204|0.125||||0.707|0.417|22.57|26.5
new_0222_0360|TARS|202109|187.088|183.801||1.709||11.27|10.365|0.905||179.142|-31.821||||46.7753|1.3742|||2.4866|||||1.5917|0.139|2.01|0.004|||6|2.8069|||20.6413||-0.76|6.671|20.6711||20.6711||17.7463|-0.7436||-0.0096||-10.443|||1.24|1.175|-16.038|-15.697|0.008|21.55|21.55|261.6612|23931.9667|44.8096|329022|||7.1428|68.0095|-0.4667|5.3333|-62.856|-76.75|-0.76|1.24|62.3656|6.55|56.8|1|5|-0.41|-5.3525|10.209|0.083||||1.357|0.517|27.76|26.6
new_0222_0360|TARS|202112|||||||||||||||50.3095||||2.597|||||1.5725||||||5|2.0169||80.1931||||||||||||||||||||||22.5|22.5|281.4315|22253.0667|-45.5601|325150|||58.4586|26.608|-0.765|4.866|||||49.0662|7.9583|54.7143|1.1429|7|-0.585|-4.902||||||||20.07|16
new_0222_0360|TARS|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-1.02|5.2075||||||||||||||||||||
new_0222_0360|TARS|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-1.0225|5.2075||||||||||||||||||||
new_0222_0360|TARS|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-1.35|||||||||||||||||||||
new_0222_0360|TARS|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-1.38|||||||||||||||||||||